Tuberculosis Arthritis in the Wrist While Using Rituximab for Rheumatoid Arthritis Treatment

References

• Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology. 2018;57(6):997–1001. doi:10.1093/rheumatology/key02329529307
   PubMed Web of Science ®Google Scholar
• Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909–920. doi:10.1136/ard.2010.14499821378402
   PubMed Web of Science ®Google Scholar
• Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm. 2017;2017:8909834. doi:10.1155/2017/890983428659665
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi:10.1136/annrheumdis-2013-20457324161836
   PubMed Web of Science ®Google Scholar
• Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24(Suppl 2):71–82. doi:10.1016/j.cmi.2018.02.003
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26. doi:10.1002/art.39480
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-a (TNF- a) targeted biologics and recently licensed TNF-a inhibitors: data from clinical trials and national registries. J Rheumatol. 2014;91:56–64.
   Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO III, et al. Longterm safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496–1502. doi:10.1136/annrheumdis-2012-20195623136242
   PubMed Web of Science ®Google Scholar
• Wendler J, Burmester GR, Sörensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, noninterventional study in 2484 patients. Arthritis Res Ther. 2014;16:R80. doi:10.1186/ar452124670196
   PubMed Web of Science ®Google Scholar
• Liao TL, Lin CH, Chen YM, Chang CL, Chen HH, Chen DY. Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan. PLoS One. 2016;11(4):e0153217. doi:10.1371/journal.pone.015321727064275
   PubMed Web of Science ®Google Scholar
• Alkadi A, Alduaiji N, Alrehaily A. Risk of tuberculosis reactivation with rituximab therapy. Int J Health Sci. 2017;11(2):41–44.
   Google Scholar
• Pehlivan Y, Kisacik B, Bosnak VK, Onat AM. Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis. BMJ Case Rep. 2013;2013:bcr2012006585. doi:10.1136/bcr-2012-006585
   Google Scholar
• Burr ML, Malaviya AP, Gaston JH, Carmichael AJ, Ostor AJK. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology. 2008;47(5):738–739. doi:10.1093/rheumatology/ken11318375402
   PubMed Web of Science ®Google Scholar
• Jung N, Owczarczyk K, Hellmann M, et al. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology. 2008;47:932–933. doi:10.1093/rheumatology/ken14318417524
   PubMed Web of Science ®Google Scholar
• Xanthouli P, Sailer S, Fiehn C. Rituximab (RTX) as an alternative to TNF-alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections: a systematic analysis of the experience in one center. Open Rheumatol J. 2012;6:286–289. doi:10.2174/187431290120601028623002410
   PubMedGoogle Scholar
• Ottaviani S, Tiendrebeogo J, Choudat L, et al. Knee tuberculosis under rituximab therapy for rheumatoid arthritis. Joint Bone Spine. 2013;80(4):435–436. doi:10.1016/j.jbspin.2012.10.01823238006
   PubMed Web of Science ®Google Scholar
• Gazaix-Fontaine E, Ottaviani S, Dieudé P. Pleural tuberculosis under rituximab therapy for anti-synthetase syndrome. Scand J Rheumatol. 2018;47:338–339. doi:10.1080/03009742.2017.134051428784035
   PubMed Web of Science ®Google Scholar
• Parikh N, Shukla D, Chandani Parikh KU, Pandya S, Malhotra S, Patel P. A case series of rituximab induced tuberculosis. Int J Basic Clin Pharmacol. 2018;7(12):2468–2471.
   Google Scholar
• Winthrop KL, Yamashita S, Beekmann E, Polgreen PM; on behalf of the Infectious diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis. 2008;46(11):1738–1740. doi:10.1086/58798918419421
   PubMed Web of Science ®Google Scholar
• Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010;10(4):236–247. doi:10.1038/nri272920224569
   PubMed Web of Science ®Google Scholar